Development and Validation of a Kidney-Transplant Specific Measure of Treatment Burden

Elizabeth C. Lorenz1,2*, Tanya M. Petterson3, Isabella Zaniletti4, Kandace A. Lackore3, Bradley K. Johnson3, Martin L. Mai1,5, Sumi S. Nair1,6, Andrew J. Bentall1,2, Kathleen J. Yost7 and David T. Eton8

Abstract

Background: Treatment burden refers to the work involved in managing one’s health and its impact on well-being and has been associated with nonadherence in patients with chronic illnesses. No kidney transplant (KT)-specific measure of treatment burden exists. The aim of this study was to develop a KT-specific supplement to the Patient Experience with Treatment and Self-Management (PETS), a general measure of treatment burden.

Methods: After drafting and pretesting KT-specific survey items, we conducted a cross-sectional survey study involving KT recipients from Mayo Clinic in Minnesota, Arizona, and Florida. Exploratory factor analysis (EFA) was used to identify domains for scaling the KT-specific supplement. Construct and known-groups validity were determined.

Results: Survey respondents (n = 167) had a mean age of 61 years (range 22–86) and received a KT on average 4.0 years ago. Three KT-specific scales were identified (transplant function, self-management, adverse effects). Higher scores on the KT-specific scales were correlated with higher PETS treatment burden, worse physical and mental health, and lower self-efficacy (p < 0.0001). Patients taking more medications reported higher transplant self-management burden.

Conclusions: We developed a KT-specific supplement to the PETS general measure of treatment burden. Scores may help providers identify recipients at risk for nonadherence.

Keywords: Treatment Burden, Kidney Transplant, Quality of Life, Adherence, Chronic Kidney Disease

Background

Kidney transplantation (KT) is the treatment of choice for patients with end-stage kidney disease (ESKD) because it is associated with better patient survival, cost, and quality of life (QOL) compared to dialysis [1, 2]. Unfortunately, there is a significant organ shortage, and over 90,000 patients in the United States are currently waiting for a KT [3, 4]. Once a patient receives a deceased donor kidney transplant, it only lasts an average of 12 years [5]. In a recent position statement, the National Kidney Foundation highlighted extending transplant longevity as a critical research priority [2]. A major contributor to KT failure is nonadherence [6]. Nonadherence to immunosuppressive therapy has been observed in approximately 25% of KT recipients who face a complex regimen of medications, laboratory monitoring, and medical appointments [6]. However, adherence involves more than just taking medications. The World Health Organization defines adherence as a multidimensional construct which also involves instituting dietary and
lifestyle changes recommended by health care providers [7].

A potentially unrecognized contributor to nonadherence in KT recipients is treatment burden. Treatment burden refers to the work involved in taking care of one's health and the impact of that work on personal well-being [8]. The work involved in taking care of one's health is multifaceted and includes not only taking medications, but also seeking and understanding medical information, health monitoring, maintaining medical appointments, diet, and exercise [9, 10]. Treatment burden has been associated with nonadherence, difficulty navigating the healthcare system, and decreased QOL in non-transplant patients [8, 11–14]. Fortunately, treatment burden appears amenable to interventions like simplifying medication regimens and increasing home-based care [15].

Despite the clinical significance and potential reversibility of treatment burden, it is understudied in patients with chronic kidney disease (CKD), including KT recipients. Currently, there are no validated measures of treatment burden in KT recipients. Our overall goal is to adapt the Patient Experience with Treatment and Self-Management (PETS) [8], a measure of treatment burden developed in patients with multiple chronic diseases, for use after KT. We previously completed the first two steps toward this goal (Fig. 1). Specifically, we developed a conceptual framework of treatment burden after KT by conducting qualitative interviews and focus groups with KT recipients [16]. We found that the domains of the general PETS measure were relevant and applicable after KT, but that KT recipients also experience KT-specific burden. The purpose of this study to develop and validate a new KT-specific measure of treatment burden by adding a module of supplementary items to the core PETS measure.

Methods

Study participants

Our study was approved by the Mayo Clinic Institutional Review Board (#19–001,693). Inclusion criteria included: 1) 18 years of age or older and 2) received a KT at Mayo Clinic in Minnesota, Mayo Clinic Arizona, or Mayo Clinic Florida. Exclusion criteria included: 1) neuropsychiatric condition causing patient to be unable to provide consent, 2) non-English speaking, and 3) failed KT defined as return to dialysis or relisting for KT. Oral consent and Health Insurance Portability and Accountability authorization were obtained.

Cognitive pre-testing

Based on the KT-specific issues of treatment burden we identified in our prior qualitative study [16], we drafted 14 items for a supplement to the PETS. Cognitive pre-testing of these 14 items was conducted with KT recipients from Mayo Clinic in Minnesota, Mayo Clinic Arizona, or Mayo Clinic Florida between 2/2020 and 4/2020. We conducted two rounds of interviews either in person or via telephone. Six participants participated in the first round of interviews, and 5 participants participated in the second round of interviews. During each round, the interviewer asked participants to complete the module of items, comment on their understanding of
within the past 10 years, including 150 patients from a random sample of 300 patients who had received KT. We determined we would invite 300 patients to complete the PETS [8], we expected a survey response rate of 35% experience surveying KT recipients [26] and validating least 102 participants would be needed. Based on prior groups validity, we determined that a sample size of at least 102 participants would be needed. Based on prior experience surveying KT recipients [26] and validating the PETS [8], we expected a survey response rate of 35% and determined we would invite 300 patients to complete the survey packet. Survey packets were thus mailed to a random sample of 300 patients who had received KT within the past 10 years, including 150 patients from Mayo Clinic in Minnesota, 75 patients from Mayo Clinic Arizona, and 75 patients from Mayo Clinic Florida. To maximize response rate, a second mailing was sent to nonrespondents one month after the first mailing. Patients who still did not respond received a phone call reminder from the Mayo Clinic Survey Research Center, and the survey packet was resent if needed. An additional 122 survey packets were distributed to patients presenting for routine transplant clinic appointments at Mayo Clinic in Minnesota. The period of survey recruitment was from 10/2020 through 6/2021. Participants who completed a survey packet received remuneration ($10).

**Data analysis**

Data were summarized by mean, median, standard deviation and range for continuous variables, and counts and percentages for categorical variables. Demographics, medications, and information about the patient’s medical history were abstracted from the electronic medical record. Estimated glomerular filtration rate within 12 months of survey completion was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation [27]. All analyses except for exploratory factor analysis outlined below were conducted in SAS 9.4. An overview of subsequent steps involved in validating the KT-specific measure of treatment burden is outlined in Fig. 2.

**Exploratory factor analysis**

An exploratory factor analysis (EFA) was performed on items within the KT-specific supplement to determine whether there were underlying patterns in the data that could justify aggregation of items into domain scales. Factors were extracted based on two standard criteria: eigenvalues > 1.0 and examination of the scree plot. Principal axis factoring (PAF) was used to extract factors followed by a non-orthogonal oblique rotation (promax) to facilitate interpretation of individual factors, and final item communalities ($h^2$), the common variance of an item accounted for by the factors, were calculated. Factor analysis was conducted in IBM SPSS 28.0. Based on the EFA results, the KT-specific items were aggregated into scales.

**Scale scoring**

KT-specific supplement scales were scored using previously published PETS scoring methods [8]. Briefly, raw scale scores were converted to a 0–100 scale with higher scores indicating higher burden. Scale scores were determined as long as >50% of the items within the scale were non-missing. Items rated as not applicable were treated as missing. Correlations among scale scores were also examined using Spearman’s rank-order correlations.

Survey administration

The Mayo Clinic Survey Research Center prepared the survey packet for mailing. Each packet included a cover letter, a postage-paid return envelope and the following surveys: our 14-item KT-specific module of supplemental questions; the 60-item general PETS (version 2.0) [8] assessing treatment burden; the 10-item Patient-Reported Outcomes Measurement Information System (PROMIS) Global-10 (version 1.0) assessing physical and mental health [17]; the 25-item Burden, Symptoms/Problems and Effects of Kidney Disease scales of the Kidney Disease Quality of Life Short-Form (KDQOL-SF) (version 1.3) [18–20] assessing health-related quality of life; the 5-item side effects and 3-item convenience subscales of the Treatment Satisfaction Questionnaire for Medication (TSQM) [21] assessing difficulties taking medications and medication side effects; and the 8-item Perceived Medical Condition Self-Management Scale (PMCSM) [22, 23] assessing self-efficacy in managing one’s health. Education, work status, number of prescription medications, medication adherence [24], convenience of healthcare services and financial distress related to healthcare costs were assessed using single items. Subjective health literacy was assessed using three items, including difficulty understanding written information, spoken information, and filling out forms [25].

To have 80% power to detect an effect size of 0.5 at the one-tailed 5% significance level and calculate known-groups validity, we determined that a sample size of at least 102 participants would be needed. Based on prior experience surveying KT recipients [26] and validating the PETS [8], we expected a survey response rate of 35% and determined we would invite 300 patients to complete the survey packet. Survey packets were thus mailed to a random sample of 300 patients who had received KT within the past 10 years, including 150 patients from Mayo Clinic in Minnesota, 75 patients from Mayo Clinic Arizona, and 75 patients from Mayo Clinic Florida. To maximize response rate, a second mailing was sent to nonrespondents one month after the first mailing. Patients who still did not respond received a phone call reminder from the Mayo Clinic Survey Research Center, and the survey packet was resent if needed. An additional 122 survey packets were distributed to patients presenting for routine transplant clinic appointments at Mayo Clinic in Minnesota. The period of survey recruitment was from 10/2020 through 6/2021. Participants who completed a survey packet received remuneration ($10).

**Data analysis**

Data were summarized by mean, median, standard deviation and range for continuous variables, and counts and percentages for categorical variables. Demographics, medications, and information about the patient’s medical history were abstracted from the electronic medical record. Estimated glomerular filtration rate within 12 months of survey completion was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation [27]. All analyses except for exploratory factor analysis outlined below were conducted in SAS 9.4. An overview of subsequent steps involved in validating the KT-specific measure of treatment burden is outlined in Fig. 2.

**Exploratory factor analysis**

An exploratory factor analysis (EFA) was performed on items within the KT-specific supplement to determine whether there were underlying patterns in the data that could justify aggregation of items into domain scales. Factors were extracted based on two standard criteria: eigenvalues > 1.0 and examination of the scree plot. Principal axis factoring (PAF) was used to extract factors followed by a non-orthogonal oblique rotation (promax) to facilitate interpretation of individual factors, and final item communalities ($h^2$), the common variance of an item accounted for by the factors, were calculated. Factor analysis was conducted in IBM SPSS 28.0. Based on the EFA results, the KT-specific items were aggregated into scales.

**Scale scoring**

KT-specific supplement scales were scored using previously published PETS scoring methods [8]. Briefly, raw scale scores were converted to a 0–100 scale with higher scores indicating higher burden. Scale scores were determined as long as >50% of the items within the scale were non-missing. Items rated as not applicable were treated as missing. Correlations among scale scores were also examined using Spearman’s rank-order correlations.
Reliability and validity

After determining scaling of the KT-specific supplement items using EFA, internal consistency reliability was determined by calculating Cronbach's $\alpha$ coefficients for each scale with $\alpha$'s $\geq 0.70$ indicating adequate reliability. Construct validity was determined by correlating scores of the KT-specific supplement scales with the general treatment burden scores of the PETS and other related constructs (i.e., adherence, quality of life, etc.). Construct validity of the KT-specific scales was supported if at least a moderate correlation was identified with the PETS scales and scores on other related constructs using Spearman rank-order correlations ($p \geq 0.30$) [28]. Known-groups validity was determined by comparing groups of patients predicted to have different levels of treatment burden (i.e., patients with diabetes compared to patients without diabetes) using independent sample t-tests.

Results

Patient characteristics

Overall, 167 participants completed a survey distributed via mail or in clinic. Of the 300 surveys distributed via mail, 125 participants responded (41.7%), including 66 of 150 participants from Mayo Clinic in Minnesota (44.0%), 27 of 75 from Mayo Clinic Arizona (36.0%), and 32 of 75 from Mayo Clinic Florida (42.7%). Of the 122 surveys distributed in clinic at Mayo Clinic in Minnesota, an additional 42 participants responded (34.4%). Demographics of all 167 participants are outlined in Table 1. Mean participant age was 60.9 (12.7) years, and the median time from KT was 4.0 (1.2–5.4) years. Overall, 55.7% of respondents were male, 84.7% were white, 82% finished some college or obtained a technical degree, 75.2% were married, and 41.2% were retired or unemployed.

Item scores

Scores from the 14 individual items within the KT-specific supplement are displayed in Table 2. Two items contained large amounts of missing data ($\geq 25\%$ of participants responding “does not apply to me”) and were therefore excluded. This included Q9 (“I have felt like I would like to communicate more with my kidney donor or the family of the person who donated my kidney”) and Q10 (“My dialysis graft or fistula [area of arm where needles went during hemodialysis] has bothered me”).

Exploratory factor analysis

An EFA performed on the remaining 12 items revealed three factors with corresponding eigenvalues of 4.06, 1.85, and 1.07. The three factors accounted for 46% of the total variance. Two items were removed from the factor model due to very low item communalities ($h^2 < 0.25$): “I feel I know enough about the person who donated my kidney” (Q8) and “I have had difficulty taking my anti-rejection medications as directed” (Q13).

The EFA was re-run on the remaining 10 items and once again revealed three factors, with corresponding eigenvalues of 3.94, 1.73, and 1.01. The three factors accounted for 53% of the total variance. An oblique pro-max rotation was used to facilitate interpretation of the loadings of the extracted factors. Factor loadings and item communalities appear in Supplemental Table 2. The first factor included items assessing concern about loss of KT function, return to dialysis, rejection, or recurrent disease (Q1, 3, 4, 5) and was labelled “transplant function.” The second factor included items assessing confidence in one’s ability to take care of the KT and feeling responsible for the KT (Q2, 6, 7) and was labelled “transplant self-management.” The third factor included concern about side effects of immunosuppression (Q11, 12, 14) and was labelled “transplant adverse effects.” Final item communalities ranged from 0.36 to 0.78.

Based on the EFA results, the KT-specific items were aggregated into three domain scales (i.e., transplant function, transplant self-management, and transplant adverse effects) with standard PETS scoring used to determine domain scale scores [8]. Spearman’s correlations of each of the three KT-specific scales were displayed in Supplemental Table 2. Mean scale scores of the PETS measure, the newly derived KT-specific scales, and the other measures included in the survey are displayed in Table 3.

Reliability, construct validity, and known-groups validity

Internal reliabilities for the three KT-specific supplement scales were the following: Cronbach’s $\alpha = 0.83$ for transplant function, $\alpha = 0.72$ for transplant self-management, and $\alpha = 0.66$ for transplant adverse effects. In terms of construct validity, all three scales of the KT-specific supplement were positively and significantly correlated with the treatment burden scores of the PETS scales (Supplemental Table 4). Higher scores on the transplant function scale were most strongly correlated with higher burden on the medical and healthcare expenses scale of the PETS ($\rho = 0.36$), higher scores on the transplant self-management scale were most strongly correlated with higher burden on the monitoring health scale of the PETS ($\rho = 0.47$), and higher scores on the transplant adverse effects scale were most strongly correlated with higher burden on the medication side effects bother scale of the PETS ($\rho = 0.52$).

Similarly, higher scores on the KT-specific supplement scales were associated with scores on established measures of general physical and mental wellbeing, kidney disease-specific quality of life, medication satisfaction, and self-efficacy (Supplemental Table 5). Higher scores on the KT-specific supplement scales were significantly
### Table 1  Demographics of survey respondents

| Characteristics of Respondents | N = 167 |
|--------------------------------|---------|
| Age (years), mean (range)      | 60.9 (21.7–86.1) |
| Male, N (%)                    | 93 (55.7) |
| Race, N (%)                    |         |
| White                          | 138 (84.7) |
| Black/African-American         | 9 (5.5)  |
| Asian                          | 6 (3.7)  |
| American Indian/Alaskan Native | 4 (2.5)  |
| Mixed race (more than one race)| 4 (2.5)  |
| Other                          | 2 (1.2)  |
| Hispanic/Spanish/Latino ethnicity, N (%) | 7 (4.2) |
| Marital status, N (%)          |         |
| Never married                  | 15 (9.1) |
| Married                        | 124 (75.2) |
| Living with partner            | 7 (4.2)  |
| Separated, divorced, widowed   | 19 (11.5) |
| Education level, N (%)         |         |
| 8th grade or less              | 1 (0.6)  |
| Some high school               | 1 (0.6)  |
| High school graduate/GED       | 28 (16.8) |
| Some college/technical degree  | 57 (34.1) |
| College graduate               | 50 (29.9) |
| Advanced degree                | 30 (18.0) |
| Work status, N (%)             |         |
| Full-time employed             | 58 (35.2) |
| Part-time employed             | 15 (9.1)  |
| Homemaker                      | 6 (3.6)  |
| Retired or unemployed          | 68 (41.2) |
| On disability or leave         | 18 (10.9) |
| Current yearly household income, N (%) |         |
| Less than $20,000              | 16 (10.4) |
| $20,000 to $29,999             | 13 (8.4)  |
| $30,000 to $39,999             | 6 (3.9)  |
| $40,000 to $59,999             | 23 (14.9) |
| $60,000 to $79,999             | 23 (14.9) |
| $80,000 to $99,999             | 21 (13.6) |
| $100,000 or more               | 52 (33.8) |
| Current living situation, N (%)|         |
| Living in a home               | 150 (90.4) |
| Living in an apartment         | 11 (6.6)  |
| Assisted living/nursing home   | 1 (0.6)  |
| Homeless                       | 1 (0.6)  |
| Other                          | 3 (1.8)  |
| Including yourself, current number people residing in your home, N (%) |         |
| 2                              | 92 (60.9) |
| 3                              | 19 (12.6) |
| 4 or more                      | 16 (10.6) |
| Time from kidney transplant (years), mean (range) | 4.0 (0.3–24.2) |
| Donor type, N (%)              |         |
| Deceased                       | 55 (32.9) |
Table 1 (continued)

| Characteristics of Respondents                                                                 | N = 167 |
|------------------------------------------------------------------------------------------------|---------|
| Living related                                                                                 | 42 (25.1) |
| Living unrelated                                                                               | 70 (41.9) |
| Prior kidney transplant, N (%)                                                                  | 16 (9.6) |
| History of pre-transplant dialysis, N (%)                                                       | 93 (55.7) |
| Cause of end-stage renal disease, N (%)                                                         |         |
| Glomerulonephritis                                                                            | 48 (28.7) |
| Diabetes                                                                                       | 30 (18.0) |
| Polycystic kidney disease                                                                      | 36 (21.6) |
| Other or unknown                                                                               | 53 (31.7) |
| Estimated glomerular filtration rate (GFR) (ml/min/1.73 m2), mean (range)                     | 49.0 (15–90) |
| Comorbidities, N (%)                                                                           |         |
| Diabetes                                                                                       | 51 (30.5) |
| Hepatitis                                                                                      | 2 (1.2)  |
| Glaucoma                                                                                       | 4 (2.4)  |
| Depression                                                                                     | 38 (22.8) |
| Asthma                                                                                         | 10 (6.0)  |
| Osteoarthritis                                                                                 | 9 (5.4)  |
| Hyperlipidemia                                                                                 | 117 (70.1) |
| Hypertension                                                                                   | 151 (90.4) |
| Coronary artery disease                                                                        | 28 (16.8) |
| Cancer                                                                                         | 39 (23.4) |
| Congestive heart failure                                                                       | 9 (5.4)  |
| Inflammatory arthritis                                                                        | 7 (4.2)  |
| Number of comorbidities, N (%)                                                                 |         |
| 1                                                                                              | 43 (25.7) |
| 2                                                                                              | 49 (29.3) |
| 3                                                                                              | 48 (28.7) |
| 4                                                                                              | 27 (16.2%) |
| Median number of conditions                                                                    | 3.0      |
| Number of medications, mean (range)                                                            | 11.5 (3.0–21.0) |
| Immunosuppression, N (%)                                                                       |         |
| Tacrolimus                                                                                     | 150 (98.9) |
| Cyclosporine                                                                                   | 8 (4.8)  |
| Belatacept                                                                                     | 6 (3.6)  |
| Sirolimus                                                                                      | 3 (1.8)  |
| Prednisone maintenance, N (%)                                                                   | 122 (73.1) |
| History of acute rejection, N (%)                                                                | 40 (24.0) |
| Estimated glomerular filtration rate (GFR) (ml/min/1.73 m2), mean (range)                     | 49 (15–90) |
| Smoking history, N (%)                                                                         |         |
| Actively smoking                                                                               | 3 (1.8)  |
| Prior smoker                                                                                   | 63 (38.0) |
| Never smoker                                                                                    | 100 (60.2) |
| Adherence to medications, N (%)                                                                 |         |
| Always take all medications                                                                    | 158 (94.6) |
| Usually take all medications (85% of time)                                                     | 8 (4.8)  |
| Sometimes take all medications (< 80% of time)                                                 | 1 (0.6)  |
| How often do you have problems learning about your medical condition because of difficulty understanding written information? N (%) |
| All of the time                                                                                | 2 (1.2%)  |
| Most of the time                                                                              | 0 (0.0%)  |
correlated with worse physical and mental health (PROMIS-10); worse burden, symptoms/problems, and effects of kidney disease (KDQOL-SF); more bother due to medication side effects (TSQM side effects); and lower self-efficacy for managing chronic illness (PMCSM). Most of the correlations (86%) were of medium size or greater ($\rho \geq 0.30$) supporting construct validity of the KT-specific supplement scales.

Scores on the KT-specific supplement scales were also compared across groups of patients to assess known-groups validity (Supplemental Table 6). We found that patients with diabetes, patients with more comorbidities, patients taking more medications, and patients transplanted > 1 year ago had significantly higher burden scores on the transplant self-management scale. Patients with an eGFR < 30 ml/min/1.73 m² had significantly higher burden scores on the transplant function scale and a trend toward significantly higher burden scores on the transplant adverse effects scale (54.2±29.7 versus 32.1±24.6, $p=0.004$ and 54.9±30.5 versus 41.6±23.6, $p=0.07$, respectively).

**Discussion**

The purpose of this study was to develop and validate a KT-specific supplementary module to the PETS general measure of treatment burden. Based on our previously developed conceptual framework of treatment burden after KT [16], we drafted items for a KT-specific supplement and then pretested them during cognitive interviews. The supplementary items were pilot tested in a
A cross-sectional survey study of 167 KT recipients from three geographically dispersed Mayo Clinic transplant centers. Exploratory factor analysis supported three scales within the KT-specific supplement, including transplant function, transplant self-management, and transplant adverse effects. Internal reliability was acceptable (alpha ≥ 0.70) for the transplant function and transplant self-management scales, but slightly lower in the transplant adverse effects scale (alpha = 0.66), possibly due to qualitative differences in the adverse effects queried (i.e., development of another health condition versus medication side effects). Construct validity of our supplement was demonstrated by correlating scores on the three scales with scores of general treatment burden (i.e., the PETS) and other established measures of established constructs. Scores on several of the KT-specific scales were quite high relative to scores on the PETS suggesting that the supplement may provide additional information regarding treatment burden in KT recipients compared to the general measure.

Scores on the KT-specific supplementary scales were associated with differences in patient characteristics. We found that patients with diabetes, more comorbidities, and more medications reported significantly higher burden on the transplant self-management scale. Prior studies have also demonstrated an association between treatment burden, comorbidities, and medications [29–31]. KT recipients forced to manage multiple comorbidities and complex medication regimens may perceive a greater sense of responsibility and self-management burden. We also found that patients who received a KT > 1 year ago reported significantly higher burden on the transplant self-management scale. This higher self-management burden may be related to less frequent follow-up and guidance from transplant centers after the first post-transplant year. Our finding that patients with an eGFR < 30 ml/min/1.73 m² reported significantly higher burden on the transplant function scale is not surprising. Patients with reduced function may be aware that they are closer to needing to start dialysis or undergo retransplantation; KT recipients often view allograft failure as an outcome worse than death [32].

Although patients seen by nephrologists have been shown to be more medically complex, have more comorbidities, and take more medications than patients seen by other subspecialists [33], little is known about treatment burden in patients with CKD. The few studies conducted in this vulnerable population have shown that more than one-third of patients with pre-dialysis and dialysis-dependent CKD experience moderate to high treatment burden, and that treatment burden is associated with decreased quality of life and reduced social support [34, 35]. Even less is known about treatment burden after KT. KT recipients may be especially vulnerable to excessive treatment burden given their potentially fragmented healthcare and the long-term side effects and cost of immunosuppression.

### Table 2

Scores from original items within the kidney-transplant specific supplement

| Item                                                                 | N   | Mean (SD) | Score range | Not Applicable or Missing |
|---------------------------------------------------------------------|-----|-----------|-------------|---------------------------|
| Q1. I have been concerned my KT is losing function                   | 160 | 2.98 (0.96) | 1.00–4.00   | 7                         |
| Q2. I have been confident that I am taking good care of my KT       | 163 | 1.67 (0.72) | 1.00–4.00   | 4                         |
| Q3. I have been concerned that I will have to started dialysis in the future | 154 | 3.04 (0.96) | 1.00–4.00   | 13                        |
| Q4. I have been concerned about my body rejecting my KT             | 160 | 2.88 (0.93) | 1.00–4.00   | 7                         |
| Q5. I have been concerned that my original kidney disease will return and affect the function of my KT | 146 | 2.90 (0.97) | 1.00–4.00   | 21                        |
| Q6. I have been confident that I will never do anything that will hurt my KT | 163 | 1.79 (0.79) | 1.00–4.00   | 4                         |
| Q7. I feel responsible for my kidney transplant doing well          | 163 | 1.48 (0.57) | 1.00–3.00   | 4                         |
| Q8. I feel that I know enough about the person who donated my kidney| 156 | 1.79 (1.03) | 1.00–4.00   | 11                        |
| Q9. I have felt like I would like to communicate more with my kidney donor or the family of the person who donated my kidney | 126 | 2.66 (1.01) | 1.00–4.00   | 41                        |
| Q10. My dialysis graft or fistula has been bothering me              | 76  | 2.92 (1.04) | 1.00–4.00   | 91                        |
| Q11. I have been concerned about developing an infection of any type | 161 | 2.61 (0.98) | 1.00–4.00   | 6                         |
| Q12. I have been concerned about developing a cancer of any type     | 162 | 2.69 (0.89) | 1.00–4.00   | 5                         |
| Q13. I have had difficulty taking my anti-rejection medications as directed | 164 | 3.55 (0.72) | 1.00–4.00   | 3                         |
| Q14. I have been bothered by side effects of my anti-rejection medications | 163 | 2.87 (1.03) | 1.00–4.00   | 4                         |

1 All items use the following response scale: 1—strongly agree; 2—agree; 3—disagree; 4—strongly disagree; 5—not applicable; 2 The PETS measure, including all adaptations, derivations, and translations are protected by copyright, © 2020 Mayo Foundation for Medical Education and Research. All Rights Reserved. Queries regarding any aspect of this work should be addressed to the corresponding author.
Developing a KT-specific measure of treatment burden is an important initial step to improving treatment burden. Treatment burden has been shown to be associated with nonadherence in non-transplant patients \[8, 36\]. Thus, screening for treatment burden after KT could identify patients at high risk for nonadherence to immunosuppression. KT recipients experiencing high treatment burden might benefit from interventions shown to lessen treatment burden in patients with other chronic conditions, including simplified treatment regimens and increased home-based care \[15\]. Furthermore, a KT-specific measure of treatment burden could also serve as a benchmark in future clinical trials designed to improve adherence, QOL, and KT survival.

The study does have several limitations. First, response rates were below 50% at each of the three centers. This may have introduced a response bias. Treatment burden may have been underestimated if the most burdened KT recipients chose not to participate in the study. Second, although our respondents received KT from three geographically dispersed transplant centers, all three were Mayo Clinic centers. Thus, results may be less generalizable to patients receiving transplants at other centers, including centers outside the United States. Interestingly, treatment burden as measured by the PETS has been found to be relevant to patients with chronic health conditions in other countries with different healthcare systems, including the United Kingdom and Norway \[37–39\]. Third, our cohort had relatively low representation of racial/ethnic minorities and the less formally educated, and future studies should include a more diverse cohort. Lastly, our study was conducted during the coronavirus disease of 2019 (COVID-19) pandemic which may have impacted our results. The pandemic may have increased treatment burden by limiting access to medical care potentially leading to exacerbations of medical conditions. Immunosuppressed KT recipients may have experienced higher burden related to worry about infection and adverse impacts of isolation on social, physical, and psychological function. Conversely, the pandemic may have lessened treatment burden by providing greater access to telemedicine-based care \[40\].

### Table 3

| Scale                        | N   | Mean (SD) | Score range |
|------------------------------|-----|-----------|-------------|
| **PETS**                     | 162 | 7.4 (16.5) | 0.0–71.4    |
| **Medical information**      | 159 | 7.0 (16.5) | 0.0–92.9    |
| **Medical appointments**     | 158 | 15.1 (15.8) | 0.0–58.3    |
| **Monitoring health**        | 157 | 22.1 (22.1) | 0.0–100.0   |
| **Diet**                     | 166 | 32.6 (20.0) | 0.0–100.0   |
| **Exercise or physical therapy** | 166 | 39.5 (24.3) | 0.0–100.0   |
| **Physical/mental fatigue**  | 164 | 12.1 (16.6) | 0.0–87.5    |
| **Medical and health care expenses** | 162 | 32.3 (24.9) | 0.0–100.0   |
| **Difficulty with health care services** | 156 | 26.8 (19.5) | 0.0–90.5    |
| **Role/social activity limitations** | 162 | 16.2 (20.4) | 0.0–100.0   |
| **Physical/mental fatigue**  | 161 | 21.8 (21.3) | 0.0–90.0    |
| **Relationships with others** | 164 | 13.4 (22.5) | 0.0–100.0   |
| **Medical appointments**     | 158 | 15.1 (15.8) | 0.0–58.3    |
| **Medical information**      | 162 | 7.4 (16.5) | 0.0–71.4    |
| **Medical appointments**     | 158 | 15.1 (15.8) | 0.0–58.3    |
| **Monitoring health**        | 157 | 22.1 (22.1) | 0.0–100.0   |
| **Diet**                     | 166 | 32.6 (20.0) | 0.0–100.0   |
| **Exercise or physical therapy** | 166 | 39.5 (24.3) | 0.0–100.0   |
| **Physical/mental fatigue**  | 164 | 12.1 (16.6) | 0.0–87.5    |
| **Medical and health care expenses** | 162 | 32.3 (24.9) | 0.0–100.0   |
| **Difficulty with health care services** | 156 | 26.8 (19.5) | 0.0–90.5    |
| **Role/social activity limitations** | 162 | 16.2 (20.4) | 0.0–100.0   |
| **Physical/mental fatigue**  | 161 | 21.8 (21.3) | 0.0–90.0    |
| **Relationships with others** | 164 | 13.4 (22.5) | 0.0–100.0   |
| **Medical appointments**     | 158 | 15.1 (15.8) | 0.0–58.3    |
| **Medical information**      | 162 | 7.4 (16.5) | 0.0–71.4    |
| **Medical appointments**     | 158 | 15.1 (15.8) | 0.0–58.3    |
| **Monitoring health**        | 157 | 22.1 (22.1) | 0.0–100.0   |
| **Diet**                     | 166 | 32.6 (20.0) | 0.0–100.0   |
| **Exercise or physical therapy** | 166 | 39.5 (24.3) | 0.0–100.0   |
| **Physical/mental fatigue**  | 164 | 12.1 (16.6) | 0.0–87.5    |
| **Medical and health care expenses** | 162 | 32.3 (24.9) | 0.0–100.0   |
| **Difficulty with health care services** | 156 | 26.8 (19.5) | 0.0–90.5    |
| **Role/social activity limitations** | 162 | 16.2 (20.4) | 0.0–100.0   |
| **Physical/mental fatigue**  | 161 | 21.8 (21.3) | 0.0–90.0    |
| **Relationships with others** | 164 | 13.4 (22.5) | 0.0–100.0   |

1 Standard deviation; 2 Scores for surveys range from 0 (lowest) to 100 (highest) with PEMS ranging from 8 (lowest) to 40 (highest); 3 Patient Experience with Treatment and Self-Management; 4 Patient-Reported Outcomes Measurement Information System (T-Score); 5 Kidney Disease Quality of Life Short-Form; 6 Treatment Satisfaction Questionnaire for Medication; 7 Perceived Medical Condition Self-Management Scale

**Conclusions**

We utilized our previous conceptual framework of treatment burden after KT \[16\] to develop and validate a KT-specific supplement to the PETS, a general measure of treatment burden in patients with multiple chronic conditions \[8\]. The supplement contains three KT-specific scales: transplant function, transplant self-management, and transplant adverse effects. Our analyses provided support for the reliability, construct, and known-groups validity of these scales. Patients with reduced renal allograft function may be at especially high risk of burden. A KT-specific measure of treatment burden may promote identification of recipients at risk for nonadherence and graft loss, allow for modification of treatment regimens and ultimately improve patient-centered care, QOL, adherence, and long-term KT survival.

**Abbreviations**

KT: Kidney Transplantation; ESKD: End-Stage Kidney Disease; QOL: Quality of Life; CKD: Chronic Kidney Disease; PETS: Patient Experience with Treatment and Self-Management; PROMIS: Patient-Reported Outcomes Measurement
Information System; KDQOL-SF: Kidney Disease Quality of Life instrument Short-Form; TSQM: Treatment Satisfaction Questionnaire for Medication; PMCSM: Perceived Medical Condition Self-Management Scale; EFA: Exploratory Factor Analysis.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12882-022-02923-3.

Additional file 1: Supplemental Table 1. Changes made to items of the kidney-transplant specific supplement during cognitive pre-testing. Supplemental Table 2. Rotated factor loadings and final item communalities for the kidney-transplant specific supplement. Supplemental Table 3. Spearman’s rank order correlations for kidney-transplant specific supplement scales generated by exploratory factor analysis. Supplemental Table 4. Spearman’s rank-order correlations for kidney-transplant specific supplement scales with PETS scales. Supplemental Table 5. Spearman’s rank-order correlations for kidney-transplant specific supplement scales with other survey measures. Supplemental Table 6. Comparison of scores for kidney-transplant specific supplement scales among different clinical groups.

Acknowledgements
Not applicable.

Authors’ contributions
EL, AB, MM, SN, and DE contributed to the design of the research. EL, BJ, KL, TP, and DE contributed to the acquisition of the data. EL, TP, IZ, and DE contributed to the interpretation of the data, drafting and critical revision of the manuscript. All authors read and approved the final manuscript.

Funding
Dr. Lorenz is supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (Award Number DK 123313). This study was also supported by the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery.

Availability of data and materials
The de-identified datasets generated and analyzed during this study are not publicly available due to privacy concerns but are available from the corresponding author on reasonable request. The PETS measure, including all adaptations, derivations, and translations are protected by copyright, © 2020 Mayo Foundation for Medical Education and Research. All Rights Reserved. Queries regarding any aspect of this work should be addressed to the corresponding author.

Declarations

Ethics approval and consent to participate
Our study was approved by the Mayo Clinic Institutional Review Board (#19–001693), and oral consent was obtained from participants. All research was performed in accordance with the Declaration of Helsinki. We received a waiver of documentation of informed consent (e.g. oral consent) from the Mayo Clinic Institutional Review Board.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 William J Von Liebig Center for Transplantation and Clinical Regeneration, Rochester, MN, USA. 2 Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA. 3 Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA. 4 Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA. 5 Department of Transplantation, Mayo Clinic, Jacksonville, FL, USA. 6 Mayo Clinic Transplant Center, Phoenix, AZ, USA. 7 Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA. 8 Division of Health Care Delivery Research, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.

Received: 27 April 2022 Accepted: 12 August 2022
Published online: 03 September 2022

References
1. Axelrod DA, Schnitzler MA, Xiao H, et al. An economic assessment of contemporary kidney transplant practice. Am J Transplant. 2018;18(5):1168–76.
2. Lentine KL, Pastan S, Mohan S, et al. A roadmap for innovation to advance transplant access and outcomes: a position statement from the national kidney foundation. Am J Kidney Dis. 2021;78(3):119–32.
3. Harrahan S, Irani AK, Danovitch G. Long-term survival after kidney transplantation. N Engl J Med. 2021;385(8):729–43.
4. Hart A, Lentine KL, Smith JM, et al. OPTN/SRTR 2019 annual data report: kidney. Am J Transplant. 2021;21(Suppl 2):117–137.
5. Poggi ED, Augustine JJ, Arngain S, Brennan DC, Schold JD. Long-term kidney transplant graft survival-making progress when most needed. Am J Transplant. 2021;21(8):2824–32.
6. Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation. 2004;77(5):769–76.
7. Sabate E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.
8. Eton DT, Yost KJ, Lai JS, et al. Development and validation of the patient experience with treatment and self-management (PETS): a patient-reported measure of treatment burden. Qual Life Res. 2017;26(2):489–503.
9. Eton DT, Ramalho de Oliveira D, Egginton JS, et al. Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study. Patient Relat Outcome Meas. 2017;2(1):39–49.
10. Eton DT, Ridgeway JL, Egginton JS, et al. Finalizing a measurement framework for the burden of treatment in complex patients with chronic conditions. Patient Relat Outcome Meas. 2015;6:117–26.
11. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002;288(22):2880–3.
12. May CR, Eton DT, Boehmer K, et al. Rethinking the patient: using burden of treatment theory to understand the changing dynamics of illness. BMC Health Serv Res. 2014;14:281.
13. Ortenblad L, Meillier L, Jonsson AR. Multi-morbidity: a patient perspective on navigating the health care system and everyday life. Chronic Illn. 2018;14(4):271–82.
14. Tran VT, Harrington M, Montori VM, Barnes C, Wicks P, Ravaud P. Adaptation and validation of the treatment burden questionnaire (TBQ) in english using an internet platform. BMC Med. 2014;12:109.
15. Lesage A, Leclere B, Moret L, Le Glatin C. Decreasing patient-reported burden of treatment: a systematic review of quantitative interventional studies. PLoS ONE. 2021;16(1):e0245112.
16. Lorenz EC, Egginton JS, Stegall MD, et al. Patient experience after kidney transplant: a conceptual framework of treatment burden. J Patient Rep Outcomes. 2019;3(1):8.
17. Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009;18(7):873–80.
18. Baroff S, Molnar MZ, Almasi C, et al. Validation of the kidney disease quality of life-short form questionnaire in kidney transplant patients. J Psychosom Res. 2006;60(5):495–504.
19. Hays RD, Amin N, Leplege A, et al. Kidney disease quality of life short form (KDQOL-SFtm), version 1.2: a manual for use and scoring (French questionnaire, France). Santa Monica, CA: RAND; 1997.
20. Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res. 1994;3(5):329–38.
21. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.
22. Wallston KA, Osborn CY, Wagner LJ, Hilker KA. The perceived medical condition self-management scale applied to persons with HIV/AIDS. J Health Psychol. 2011;16(1):109–15.
23. Wallston KA, Rothman RL, Cherrington A. Psychometric properties of the perceived diabetes self-management scale (PDSM). J Behav Med. 2007;30(5):395–401.
24. Schoenthaler A, Montague E, Baer Manwell L, Brown R, Schwartz MD, Linzer M. Patient-physician racial/ethnic concordance and blood pressure control: the role of trust and medication adherence. Ethn Health. 2014;19(5):565–78.
25. Chew LD, Griffin JM, Partin MR, et al. Validation of screening questions for limited health literacy in a large VA outpatient population. J Gen Intern Med. 2008;23(5):561–6.
26. Lorenz EC, Cheville AL, Amer H, et al. Relationship between pre-transplant physical function and outcomes after kidney transplant. Clin Transplant. 2017;31(5):10.1111/ctr.12952. https://doi.org/10.1111/ctr.12952. Epub 2017 Apr 17.
27. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
28. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
29. Boyd CM, Wolff JL, Giovannetti E, et al. Healthcare task difficulty among older adults with multimorbidity. Med Care. 2014;52(Suppl 3):S118–25.
30. Duncan P, Murphy M, Man MS, Chaplin K, Gaunt D, Salisbury C. Development and validation of the multimorbidity treatment burden questionnaire (MTBQ). BMJ Open. 2018;8(6): e019413.
31. Schwartz CE, Zhang J, Michael W, Eton DT, Rapkin BD. Reserve-building activities attenuate treatment burden in chronic illness: the mediating role of appraisal and social support. Health Psychol Open. 2018;5(1):205510291873440.
32. Howell M, Wong G, Rose J, Tong A, Craig JC, Howard K. Patient preferences for outcomes after kidney transplantation: a best-worst scaling survey. Transplantation. 2017;101(1):2765–73.
33. Tonelli M, Weibe N, Manns BJ, et al. Comparison of the complexity of patients seen by different medical subspecialists in a universal health care system. JAMA Netw Open. 2018;1(7):e184852.
34. Al-Mansouri A, Al-Ali FS, Hamad AI, et al. Assessment of treatment burden and its impact on quality of life in dialysis-dependent and pre-dialysis chronic kidney disease patients. Res Social Adm Pharm. 2021;17(11):1937–44.
35. Song MK, Paul S, Plantinga L, Henry C, Turberville-Trujillo L. Social networks of self-care and perceived treatment burden among patients on in-center hemodialysis. Kidney Med. 2019;1(3):97–103.
36. Schreiner N, DiGennaro S, Harwell C, Burant C, Daly B, Douglas S. Treatment burden as a predictor of self-management adherence within the primary care population. Appl Nurs Res. 2020;54:151301.
37. Austin RC, Schoonhoven L, Koutra V, Richardson A, Kalra PR, May CR. Symptoms in chronic heart failure impact on burden of treatment (SYM-PACT): a cross-sectional survey. ESC Heart Fail. 2022;9(4):2279–90.
38. Husebo AML, Dalen I, Soreide JA, Bru E, Richardson A. Cancer-related fatigue and treatment burden in surgically treated colorectal cancer patients - a cross-sectional study. J Clin Nurs. 2021. https://doi.org/10.1111/jocn.16135. Online ahead of print.
39. Husebo AML, Morken IM, Eriksen KS, Nordfonna OK. The patient experience with treatment and self-management (PETS) questionnaire: translation and cultural adaption of the Norwegian version. BMC Med Res Methodol. 2018;18(1):147.
40. Linzer M, Rogers EA, Eton DT. Reducing the burden of treatment: addressing how our patients feel about what we ask of them: a “less is more” perspective. Mayo Clin Proc. 2022;97(5):826–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.